✦ LIBER ✦

Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study

✍ Scribed by van Rooijen, J.M.; de Munck, L.; de Graaf, J.C.; Siesling, S.; de Vries, E.G.; Boers, J.E.

Book ID: 122257313
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 384 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2014.01.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Randomized Study of Trastuzumab

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

✍ Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Gua 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

The potential for trastuzumab emtansine

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies

✍ Hurvitz, S. A.; Kakkar, R. 📂 Article 📅 2012 🏛 SAGE Publications 🌐 English ⚖ 775 KB

Phase IIa Trial of Trastuzumab Emtansine

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer

✍ Miller, K. D.; Dieras, V.; Harbeck, N.; Andre, F.; Mahtani, R. L.; Gianni, L.; A 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 148 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB

Serum epidermal growth factor receptor/H

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

✍ Christopher Souder; Kim Leitzel; Suhail M. Ali; Laurence Demers; Dean B. Evans; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR, HER‐1, and __erbB__1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. ## METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme‐linked immunoadsorbent assay in a

Feasibility and pharmacokinetics of comb

Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer

✍ Suzuki, Yasuhiro; Ogiya, Rin; Oshitanai, Risa; Terao, Mayako; Terada, Mizuho; Mo 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 288 KB